Your browser doesn't support javascript.
loading
Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19.
Zhang, Xiao-Yu; Li, Tao; Wu, Haibing; Ling, Yun; Qian, Zhi-Ping; Chen, Liang.
Afiliação
  • Zhang XY; Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China.
  • Li T; Department of Tuberculosis Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China.
  • Wu H; Department of Neurosurgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China.
  • Ling Y; Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China.
  • Qian ZP; Department of Severe Hepatopathy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China.
  • Chen L; Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China.
J Inflamm Res ; 14: 287-298, 2021.
Article em En | MEDLINE | ID: mdl-33574690
OBJECTIVE: This study is to evaluate the effect of proton-pump inhibitors on the course of COVID-19. METHODS: Clinical data of moderate COVID-19 patients admitted to the Shanghai Public Health Clinical Center for treatment from January 20, 2020, to March 16, 2020, were collected. A retrospective study was conducted and the patients were divided into two groups according to whether they used proton-pump inhibitors or not. The differences in SARS-CoV-2 clearance and hospital stay between the two groups were compared by Cox proportional hazards (PH) regression models and the propensity score matching method. RESULTS: A total of 154 patients with moderate COVID-19 were included in this study, including 80 males (51.9%), 35 patients (22.7%) in the proton-pump inhibitor group, and 119 patients (77.3%) in the control group. In the proton-pump inhibitor group and the control group, the duration of the SARS-CoV-2 clearance was 7 days (95% CI, 6-9) and 7 days (95% CI, 6-11), and the duration of the hospital stay was 21 days (95% CI, 16-25) and 20 days (95% CI, 15-26), respectively. There was no significant difference between the both groups in the cumulative incidence of the SARS-CoV-2 clearance and the discharge, and the same results were obtained after the propensity score matching, all P > 0.05. There was no significant association between the use of proton-pump inhibitors and the duration of SARS-CoV-2 clearance, according to univariate analysis (HR, 1.309; 95% CI, 0.893-1.918) and multivariate analysis (HR, 1.575; 95% CI, 0.993-2.499). There was no significant association between the use of proton-pump inhibitors and the duration of hospital stay for COVID-19, according to univariate analysis (HR, 1.044; 95% CI, 0.714-1.528) and multivariate analysis (HR, 1.064; 95% CI, 0.651-1.740). CONCLUSION: The use of proton-pump inhibitors has no effect on prolonging or shortening the course of adults hospitalized with COVID-19.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article